Shedding light on neural learning to rank models for anticancer drug prioritization
PLOS One · 13.08.2026 · 21 (8) · e0345854
DOI: 10.1371/journal.pone.0345854 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 13.08.2026. Verfasst von Faraz Sarmeili und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neural Networks, Computer. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Learning to Rank (LeToR) methods have gained increasing attention in drug response prediction, offering a direct way to prioritize effective treatments for cancer cell lines. In this study, we systematically benchmark six ranking loss functions, including state-of-the-art listwise methods, and five types of molecular representations across two large-scale drug screening datasets, CTRP and PRISM. Using high-dimensional gene expression profiles and various drug fingerprints and descriptors, we evaluated models under multiple validation setups and ranking metrics. Our results demonstrate that listwise loss functions such as LambdaLoss and LambdaRank consistently excel in both early and overall ranking quality. Additionally, combining molecular fingerprints with physicochemical descriptors yielded improved performance. A novel attention-based mechanism and a modified version of RankingSHAP were integrated to enhance interpretability, uncovering key genes and substructures aligned with known biological insights. The explainability pipeline successfully distinguished estrogen receptor-positive (ER⁺) and estrogen receptor-negative (ER − ) breast cancer subtypes. The model successfully identified critical substructures in docetaxel, an FDA-approved therapy, and triptolide, which is currently undergoing clinical evaluation for breast cancer. These findings are consistent with established structure-activity relationship (SAR) data. Overall, this study presents a comprehensive evaluation framework and underscores the importance of carefully selecting loss functions and feature representations when developing robust and interpretable drug-ranking systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Computer Engineering, Sharif University of Technology, Tehran, Iran.
- Department of Computer Engineering, Amirkabir University of Technology, Tehran, Iran.
- Mosaheb Institute for Mathematical Research, Kharazmi University, Tehran, Iran.
- Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Karim Abbasi, Hamid R Rabiee
Zitieren
APA
Sarmeili, F., Ghahremani-Nezhad, B., Khalilpour, M., Abbasi, K., Dinarvand, R., & Rabiee, H. R. (2026). Shedding light on neural learning to rank models for anticancer drug prioritization. PLOS One, 21(8), e0345854. https://doi.org/10.1371/journal.pone.0345854
Vancouver
Sarmeili F, Ghahremani-Nezhad B, Khalilpour M, Abbasi K, Dinarvand R, Rabiee HR. Shedding light on neural learning to rank models for anticancer drug prioritization. PLOS One. 2026;21(8):e0345854. doi:10.1371/journal.pone.0345854
BibTeX
@article{Sarmeili2026,
author = {Sarmeili, Faraz and Ghahremani-Nezhad, Benyamin and Khalilpour, Mohammad and Abbasi, Karim and Dinarvand, Rassoul and Rabiee, Hamid R},
title = {Shedding light on neural learning to rank models for anticancer drug prioritization},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {8},
pages = {e0345854},
doi = {10.1371/journal.pone.0345854}
}
EUVIMED